Aquestive Therapeutics Inc (AQST)

$4.16 -0.18 (-4.15%)
Market Cap 539.40M
Revenue (ttm) 44.55M
Net Income (ttm) -83.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -188.06%
Debt to Equity Ratio -0.82
Volume 1,401,800
Avg Vol 1,548,272
Day's Range N/A - N/A
Shares Out 124.29M
Stochastic %K 27%
Beta 1.50
Analysts Strong Sell
Price Target $8.89

Company Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 941 1900
Address:
30 Technology Drive, Warren, United States
faz999
faz999 May. 13 at 11:37 AM
$AQST strong run up into earnings. AQST will release very positive news during ER report.
0 · Reply
shaveapenny
shaveapenny May. 13 at 11:23 AM
$AQST Oaktree would not be so willing to fund AQST if bad news was coming. Also. earnings will be a moot point, it will be the updates on Anaphylm or 108 that will move this over $5
1 · Reply
Acemaker12
Acemaker12 May. 12 at 9:37 PM
$AQST https://seekingalpha.com/news/4591496-aquestive-therapeutics-q1-2026-earnings-preview?share_source=shared_news
0 · Reply
prototyper
prototyper May. 12 at 8:44 PM
$AQST classic forced drop before the news/rip set up. Seen too many
0 · Reply
OustDB_formerly_nomas
OustDB_formerly_nomas May. 12 at 8:42 PM
$AQST how much FDA compliance info on cc other than Dan’s hyperbole?? pretty important cc, no?? or pretty impotent, cc?? 🤪
0 · Reply
h8ster
h8ster May. 12 at 8:18 PM
$AQST Everybody commenting on pps movement. It doesn't move unless the investment firm that created AQST and currently controls the company through its management placement and ownership of debt and shares, gives it permission. Just like last year when the CEO giggled about keeping the price low to allow the friend of its investment firm parent to make a low entry buy, that we will not see any advancement until Crestline allows it. There is still the massive SI block that was taken out before the FDA letter last January that is still in play. AQST, whose patient likely arranged it, will not allow that friend to be burned. Hence the pinned rage we are in. Question is, does AQSR's parent allow this to go after ER or will they tell Barber to tank it during the CC? These are all just near term dynamics. The long term will have this past $10. The politics involved with these plays are insanely corrupt and manipulative. AQST is no different and that's fine. Its just the way its is
2 · Reply
LDstocks2023
LDstocks2023 May. 12 at 7:30 PM
$AQST this thing sucks boys lol
2 · Reply
BigGainTom
BigGainTom May. 12 at 7:03 PM
$AQST love me some 420
0 · Reply
ae1213
ae1213 May. 12 at 6:27 PM
$AQST I actually like $110, don’t sell lower.
0 · Reply
ae1213
ae1213 May. 12 at 6:26 PM
$AQST @traderstock9 quoting Zoolander “you can’t read good and do other things good” Real shmucks!
0 · Reply
Latest News on AQST
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

May 12, 2026, 9:31 AM EDT - 22 hours ago

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

May 6, 2026, 7:00 AM EDT - 7 days ago

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Aquestive Therapeutics assumed with an Outperform at Oppenheimer

2026-04-24T11:41:01.000Z - 19 days ago

Aquestive Therapeutics assumed with an Outperform at Oppenheimer

AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt

Apr 16, 2026, 9:00 AM EDT - 26 days ago

AQST Lawsuit Alleges Allegedly Concealed Anaphylm NDA Deficiencies - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Allegedly Concealed Anaphylm NDA Deficiencies: SueWallSt

Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims

2026-04-15T13:51:38.000Z - 27 days ago

Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims

AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

Apr 9, 2026, 8:23 AM EDT - 4 weeks ago

AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline

Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA

2026-03-30T11:16:34.000Z - 6 weeks ago

Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA

Aquestive chief legal officer, chief compliance officer Lori Braender steps down

2026-03-20T11:11:07.000Z - 7 weeks ago

Aquestive chief legal officer, chief compliance officer Lori Braender steps down

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A.

Mar 20, 2026, 7:00 AM EDT - 7 weeks ago

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A.

AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt

Mar 12, 2026, 9:00 AM EDT - 2 months ago

AQST Lawsuit Alleges Analyst Slashed Price Target - AQUESTIVE THERAPEUTICS, INC. Investors Face Losses Following Analyst Slashed Price Target: SueWallSt

Aquestive Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 8:25 AM EDT - 2 months ago

Aquestive Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

Mar 9, 2026, 4:01 PM EDT - 2 months ago

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

Aquestive Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 10:40 AM EDT - 2 months ago

Aquestive Therapeutics Transcript: Leerink Global Healthcare Conference 2026

AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Mar 6, 2026, 2:01 PM EST - 2 months ago

AQUESTIVE THERAPEUTICS, INC. (AQST) INVESTOR ALERT Investors With Large Losses in Aquestive Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global

2026-03-05T18:20:15.000Z - 2 months ago

Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global

Aquestive Therapeutics Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 2 months ago

Aquestive Therapeutics Earnings Call Transcript: Q4 2025

Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)

2026-03-04T21:20:27.000Z - 2 months ago

Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)

Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M

2026-03-04T21:19:36.000Z - 2 months ago

Aquestive Therapeutics sees FY26 revenue $46M-$50M, consensus $47.52M

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 4, 2026, 4:01 PM EST - 2 months ago

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Aquestive Therapeutics options imply 4.2% move in share price post-earnings

2026-03-04T19:20:42.000Z - 2 months ago

Aquestive Therapeutics options imply 4.2% move in share price post-earnings

Aquestive Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 12:00 PM EST - 2 months ago

Aquestive Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

Feb 25, 2026, 7:00 AM EST - 2 months ago

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

Feb 24, 2026, 7:00 AM EST - 2 months ago

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

Aquestive announces poster presentations on Anaphylm at AAAAI meeting

2026-02-20T12:06:15.000Z - 2 months ago

Aquestive announces poster presentations on Anaphylm at AAAAI meeting

Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer

2026-02-18T12:11:06.000Z - 2 months ago

Aquestive Therapeutics appoints Greenhawt as Chief Medical Officer

Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street

2026-02-03T13:46:32.000Z - 3 months ago

Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street

Alliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating

2026-02-02T19:05:09.000Z - 3 months ago

Alliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating

Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval

2026-02-02T15:45:14.000Z - 3 months ago

Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval

Aquestive CRL from FDA ‘clearing event,’ says Oppenheimer

2026-02-02T15:40:09.000Z - 3 months ago

Aquestive CRL from FDA ‘clearing event,’ says Oppenheimer

Aquestive Therapeutics Transcript: Status update

Feb 2, 2026, 8:00 AM EST - 3 months ago

Aquestive Therapeutics Transcript: Status update

Aquestive Therapeutics announces FDA issuance of CRL for Anaphylm

2026-02-02T12:12:20.000Z - 3 months ago

Aquestive Therapeutics announces FDA issuance of CRL for Anaphylm

US FDA declines to approve Aquestive's oral drug for allergic reactions

Feb 2, 2026, 7:10 AM EST - 3 months ago

US FDA declines to approve Aquestive's oral drug for allergic reactions

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

Feb 2, 2026, 7:00 AM EST - 3 months ago

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James

2026-01-09T14:40:36.000Z - 4 months ago

ARS Pharmaceuticals competitor gets FDA deficiency letter, says Raymond James

SPRY

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

Jan 9, 2026, 7:00 AM EST - 4 months ago

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

Aquestive Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 10:00 AM EST - 5 months ago

Aquestive Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Aquestive Therapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:00 AM EST - 6 months ago

Aquestive Therapeutics Earnings Call Transcript: Q3 2025

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

Oct 8, 2025, 7:00 AM EDT - 7 months ago

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

Aquestive Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 10:00 AM EDT - 8 months ago

Aquestive Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aquestive Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Aquestive Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

Aug 14, 2025, 6:28 AM EDT - 9 months ago

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Aug 14, 2025, 6:00 AM EDT - 9 months ago

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

Aquestive Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 9 months ago

Aquestive Therapeutics Earnings Call Transcript: Q2 2025

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:01 PM EDT - 9 months ago

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

Jul 22, 2025, 7:00 AM EDT - 10 months ago

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

faz999
faz999 May. 13 at 11:37 AM
$AQST strong run up into earnings. AQST will release very positive news during ER report.
0 · Reply
shaveapenny
shaveapenny May. 13 at 11:23 AM
$AQST Oaktree would not be so willing to fund AQST if bad news was coming. Also. earnings will be a moot point, it will be the updates on Anaphylm or 108 that will move this over $5
1 · Reply
Acemaker12
Acemaker12 May. 12 at 9:37 PM
$AQST https://seekingalpha.com/news/4591496-aquestive-therapeutics-q1-2026-earnings-preview?share_source=shared_news
0 · Reply
prototyper
prototyper May. 12 at 8:44 PM
$AQST classic forced drop before the news/rip set up. Seen too many
0 · Reply
OustDB_formerly_nomas
OustDB_formerly_nomas May. 12 at 8:42 PM
$AQST how much FDA compliance info on cc other than Dan’s hyperbole?? pretty important cc, no?? or pretty impotent, cc?? 🤪
0 · Reply
h8ster
h8ster May. 12 at 8:18 PM
$AQST Everybody commenting on pps movement. It doesn't move unless the investment firm that created AQST and currently controls the company through its management placement and ownership of debt and shares, gives it permission. Just like last year when the CEO giggled about keeping the price low to allow the friend of its investment firm parent to make a low entry buy, that we will not see any advancement until Crestline allows it. There is still the massive SI block that was taken out before the FDA letter last January that is still in play. AQST, whose patient likely arranged it, will not allow that friend to be burned. Hence the pinned rage we are in. Question is, does AQSR's parent allow this to go after ER or will they tell Barber to tank it during the CC? These are all just near term dynamics. The long term will have this past $10. The politics involved with these plays are insanely corrupt and manipulative. AQST is no different and that's fine. Its just the way its is
2 · Reply
LDstocks2023
LDstocks2023 May. 12 at 7:30 PM
$AQST this thing sucks boys lol
2 · Reply
BigGainTom
BigGainTom May. 12 at 7:03 PM
$AQST love me some 420
0 · Reply
ae1213
ae1213 May. 12 at 6:27 PM
$AQST I actually like $110, don’t sell lower.
0 · Reply
ae1213
ae1213 May. 12 at 6:26 PM
$AQST @traderstock9 quoting Zoolander “you can’t read good and do other things good” Real shmucks!
0 · Reply
ClearCities
ClearCities May. 12 at 5:06 PM
$AQST Looking forward to at minimum doublling by the time next pdufa comes around
0 · Reply
Skinny__
Skinny__ May. 12 at 4:26 PM
$AQST cmon, drag this thing lower. Daddy is getting greedy
1 · Reply
Kjs2020
Kjs2020 May. 12 at 4:21 PM
$AQST This debt refinancing seems like a good deal but without knowing the interest rate, we don’t really know. I expect that it is better than the previous 13.5% but we need the details
1 · Reply
BigGainTom
BigGainTom May. 12 at 4:08 PM
$AQST Refinancing debt to better terms is not bullish?
0 · Reply
Stone52
Stone52 May. 12 at 2:39 PM
$AQST don’t be fooled by the pumping press release. They act like they got an interest free loan which has milestones to access the funds. Yes, they are paying off an old loan and won’t have to pay that interest, but now they have a new loan with new interest. What a scam of a press release. Read between the lines!
1 · Reply
Acemaker12
Acemaker12 May. 12 at 1:51 PM
$AQST https://investors.aquestive.com/node/12056/pdf
0 · Reply
OustDB_formerly_nomas
OustDB_formerly_nomas May. 12 at 1:51 PM
$AQST literally was just going to question whether they will need to tap the equity markets again based upon the CRL. Looks less likely now.
1 · Reply
Fidael
Fidael May. 12 at 1:44 PM
$AQST We are excited to begin our relationship with Oaktree, a well-established leader within life sciences debt financing,” said Daniel Barber, CEO of Aquestive Therapeutics. “The new $150 million debt facility will help Aquestive drive growth for years to come. With this agreement, we reduce our principal debt repayments over the next three years from $45 million to zero, reduce our interest rate
1 · Reply
ClearCities
ClearCities May. 11 at 9:36 PM
$AQST i am titanium. You pull me down, but i won't fall i am titanium
2 · Reply
ae1213
ae1213 May. 11 at 7:50 PM
$AQST hahahaha, silly sally is really funny. You know what else is really likely? Take a guess! I will be with you here all the way just to watch
2 · Reply
BigGainTom
BigGainTom May. 11 at 7:27 PM
$AQST Expedited review is likely
0 · Reply
ae1213
ae1213 May. 11 at 3:57 PM
$AQST nice rally! The taste of things to come on Thursday. I know we can do it!
3 · Reply